2Coleman S, Clayton A, Mason MD, et al. Recovery of CD8 + T-cell function during systemic chemotherapy in advanced ovarian cancer [J]. Cancer Res, 2005, 65(15) : 7000-7006.
3Wu X, Feng QM, Wang Y, et al. The immunologic aspects in advanced ovarian cancer patients treated with paclitaxel and carboplatin chemotherapy [J]. Cancer Immunol Immunother, 2009. 59(2) :279-291.
4Rosenberg SA, Yang JC, Restifo NP. Cancer immunotherapy: moving beyond current vaccines [J]. Nat Med, 2004, 10 (9) : 909 -915.
5Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to tumor escape [J]. Nat Immunol, 2002, 3 ( 11 ) : 991-998.
6Schlienger K, Chu CS, Woo EY, et al. TRANCE- and CD40 ligand-matured dendritic cells reveal MHC class I-restricted T cells specific for autologous tumor in late-stage ovarian cancer patients [J]. Clin Cancer Res, 2003, 9(4) : 1517-1527.
7Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer [ J ]. N Engl J Med, 2003, 348(3) : 203-213.
8Curiel TJ, Coukos G, Zou L, et al. Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival [J]. Nat Med, 2004, 10(9) : 942- 949.
9Disis ML, Schiffman K, Guthrie K, et al. Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein-based vaccine [ J ]. J Clin Oncol, 2004, 22(10) : 1916-1925.
10Reinartz S, Kohler S, Schlebusch H, et al. Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ⅰb/Ⅱ) [J]. Clin Cancer Res, 2004, 10(5):1580-1587.
